Physician profile
Loreta Kalish
NPI 1184760423
$4,084.17
in general payments reported to CMS, 2019-2025
34 companies · $793 in 2025
The $793 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $531 · 2021: $163 · 2023: $309 · 2024: $965 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $646.26 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $551.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $370.53 | 2024-2025 | |
| Exact Sciences Corporation | $335.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $260.50 | 2019-2025 | Wegovy |
| Pfizer INC. | $236.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $217.40 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.36 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $168.10 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $165.65 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $107.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $103.24 | 2019-2020 | |
| Mannkind Corporation | $89.22 | 2019-2020 | |
| Radius Health, INC. | $64.33 | 2019-2021 | |
| Eisai INC. | $50.06 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $50.06 | 2019 | |
| Edwards Lifesciences Corporation | $43.05 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.84 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $38.17 | 2019-2023 | Belsomra |
| Ipsen Biopharmaceuticals, INC | $34.25 | 2024 | |
| Astellas Pharma US INC | $33.87 | 2019 | |
| Globus Medical, INC. | $33.08 | 2025 | Senza |
| Abbott Laboratories | $32.60 | 2019 | |
| Dynavax Technologies Corporation | $27.88 | 2023 | Heplisav-B |
| E.R. Squibb & Sons, L.L.C. | $27.56 | 2019-2020 | |
| Kyowa Kirin, INC. | $26.54 | 2024 | Crysvita |
| Abbvie INC. | $24.97 | 2025 | |
| Recordati_rare_diseases_inc. | $24.02 | 2023 | Signifor Lar, Isturisa |
| Takeda Pharmaceuticals U.S.A., INC. | $23.41 | 2020 | |
| Medtronic USA, INC. | $22.77 | 2019 | |
| Corcept Therapeutics | $18.40 | 2019 | |
| Insulet Corporation | $14.98 | 2019 | |
| Avion Pharmaceuticals | $14.38 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loreta Kalish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.